{"text": ["Ignyta\u2019s", "Drug", "Pipeline"], "created_at": "2018-01-09 20:45:03"}
{"text": ["A", "Close", "Look", "at", "Ignyta\u2019s", "Licensing", "Agreement"], "created_at": "2018-01-09 19:15:03"}
{"text": ["AbbVie", "Expects", "Peak", "Sales", "of", "$7", "Billion", "for", "Imbruvica"], "created_at": "2018-01-09 19:10:52"}
{"text": ["Assessing", "Incyte\u2019s", "3Q17", "Product", "Portfolio"], "created_at": "2018-01-09 18:25:02"}
{"text": ["Analyst", "Recommendations", "for", "Ignyta", "and", "Its", "Peers", "in", "January", "2018"], "created_at": "2018-01-09 17:41:28"}
{"text": ["How", "Was", "Incyte\u2019s", "Revenue", "Stream", "in", "3Q17?"], "created_at": "2018-01-09 16:55:03"}
{"text": ["5", "Companies", "Hit", "52-Week", "Highs"], "created_at": "2018-01-09 16:09:15"}
{"text": ["Why", "AbbVie", "Is", "Focused", "on", "Expanding", "Risankizumab\u2019s", "Label", "for", "Multiple", "Immunology", "Indications"], "created_at": "2018-01-09 15:32:17"}
{"text": ["Valeant", "on", "the", "Street:", "Analyst", "Recommendations", "in", "December", "2017"], "created_at": "2018-01-09 15:31:54"}
{"text": ["FDA", "Approvals", "Surge", "in", "2017:", "Here's", "a", "Look", "at", "the", "Numbers"], "created_at": "2018-01-09 14:04:31"}
{"text": ["The", "Swiss", "Stock", "Market", "Broke", "Out", "To", "A", "New", "All-Time", "High"], "created_at": "2018-01-09 12:14:00"}
{"text": ["Novartis", "Announces", "Initiation", "Of", "SURPASS,", "Head-to-head", "Trial", "Of", "Cosentyx"], "created_at": "2018-01-09 01:28:00"}
